PFEWhy shares have fallen in previous years:
COVID Product Demand Crash: A sharp decline in sales of the Comirnaty vaccine and Paxlovid led to revenues falling from $100.3B in 2022 to $58.5B in 2023.
"Patent Cliff" Concerns: The impending loss of exclusivity (LOE) for blockbusters like Eliquis, Ibrance, and Xeljanz by 2028 threatened $17–18B in annual revenue.
Weakened Guidance: Management repeatedly revised revenue and earnings forecasts downwards
Improving Fundamentals
Financial Stabilization: Pfizer finally broke the revenue instability cycle, ending 2025 with a series of "dual beats" (beating both EPS and revenue expectations).
Cost Efficiency: The management successfully implemented a multi-billion dollar cost-saving program. Margins are expanding even with moderate sales growth.
Dividend Yield ~ 6.7%
Catalysts for Future Growth
🔎
🔎 Full Research :
🌐 t.me/A3MInvestments
🌐 t.me/A3MInvestments
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
🔎 Full Research :
🌐 t.me/A3MInvestments
🌐 t.me/A3MInvestments
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.